Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Lispro, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

A secondary analysis of Boost and Ease-off from two double-blind, randomized, crossover hybrid closed-loop studies comparing (1) Fiasp to insulin aspart (n = 25), and (2) Lyumjev to insulin lispro (n = 26) was carried out.

Mean glucose on initialization of Boost and Ease-off, change in glucose 60 and 120 minutes after initialization, duration and frequency of use, mean glucose, and time in, above, and below target glucose range were calculated for periods of Boost use, Ease-off use, or neither.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Blood Glucose, Insulin Infusion Systems, Hypoglycemic Agents, Insulin Aspart, Insulin Lispro and Blood Glucose Self-Monitoring.

Author keywords: boost, ease-off, hybrid closed-loop, rapid-acting insulin, type 1 diabetes and ultra–rapid-acting insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart and Insulin Lispro.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Journal of diabetes science and technology), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.